Celebrating Clinical Success in Depression

Depression is a difficult problem for drug developers. Current marketed antidepressants are effective for a relatively small percentage of patients (about 20 in 100) and most require weeks of treatment to show an effect. Patients often need to try several… Read »

Welcome to 2018! What we are watching for JPM18 and the coming year…

Now that the holidays have wound down, we look forward to catching up with many of you in person as the Bionest team and many others from across the healthcare business world descend on San Francisco next week for the… Read »

A First Glimmer of Hope for Huntington’s Disease Patients

Huntington’s disease is a devastating and progressive inherited disorder that is caused by the expansion of the CAG trinucleotide sequence in the huntingtin (HTT) gene. This mutation results in abnormally long versions of the HTT protein, which progressively destroy neurons… Read »

It’s a pill. It’s a device. It’s both. FDA Approves the first Digital Drug Therapy

Adherence to prescription drug therapies is a big problem, not only for patients and drug developers, but also for payers who cover the costs of such medications and then pay to treat problems the drugs were meant to prevent. About… Read »

A New Precision Medicine Initiative in Parkinson’s Disease… and Perhaps Other Neurologic Conditions

Cancer was once considered a single disease, but today we are well aware of the many different forms this medical scourge can take, and the many molecular events that can lead to and drive unwanted cell growth. Now, a new… Read »

Giving Thanks in IO

The immuno-oncology (IO) field has a lot to be thankful for as the year comes to a close.   Not only are PD-1/PDL-1 inhibitors being rapidly approved, their use is being extended into new indications and tumor types well beyond… Read »

Kite Gains First Adult CAR-T Approval

Less than two weeks following the closing of Gilead’s acquisition of the company, Kite Pharma’s CAR-T immunotherapeutic, axicabtagene ciloleucel, has gained approval from the U.S. Food and Drug Administration as the first CAR-T therapy for an adult indication. The approval,… Read »

Gene Therapy for Inherited Retinal Disease Achieves a Historic Milestone

This has been an amazing year in the world of drug development, with three new therapeutic classes marking historic gains. We first saw Novartis’ FDA approval for the first CAR-T immunotherapy. Then Alnylam’s RNAi treatment achieved Phase 3 success, the… Read »

Search for an Alzheimer’s Treatment Goes On

Anticipation was high for the results of a Phase 3 trial of Axovant’s experimental drug, interpirdine. Sadly, the potential Alzheimer’s disease treatment failed to meet its co-primary endpoints. Patients with mild to moderate Alzheimer’s disease who were treated for 24… Read »

RNA Interference Achieves Key Milestone with Patisiran Success

It is a not uncommon phenomenon for a new discovery to attract much enthusiasm and hype — as well as investment and new company formation — only to suffer popular disillusionment a few years later as public interest turns to… Read »

1 2 3 4 5 10